JP7155144B2 - 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物 - Google Patents

組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物 Download PDF

Info

Publication number
JP7155144B2
JP7155144B2 JP2019550815A JP2019550815A JP7155144B2 JP 7155144 B2 JP7155144 B2 JP 7155144B2 JP 2019550815 A JP2019550815 A JP 2019550815A JP 2019550815 A JP2019550815 A JP 2019550815A JP 7155144 B2 JP7155144 B2 JP 7155144B2
Authority
JP
Japan
Prior art keywords
composition
light chain
factor vii
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019550815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511140A (ja
JP2020511140A5 (https=
Inventor
フ・ツィウェイ
Original Assignee
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ・ステイト・イノベーション・ファウンデーション filed Critical オハイオ・ステイト・イノベーション・ファウンデーション
Publication of JP2020511140A publication Critical patent/JP2020511140A/ja
Publication of JP2020511140A5 publication Critical patent/JP2020511140A5/ja
Application granted granted Critical
Publication of JP7155144B2 publication Critical patent/JP7155144B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019550815A 2017-03-14 2018-03-14 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物 Active JP7155144B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762471045P 2017-03-14 2017-03-14
US62/471,045 2017-03-14
US201762576278P 2017-10-24 2017-10-24
US62/576,278 2017-10-24
US201862623269P 2018-01-29 2018-01-29
US62/623,269 2018-01-29
PCT/US2018/022443 WO2018170134A1 (en) 2017-03-14 2018-03-14 Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates

Publications (3)

Publication Number Publication Date
JP2020511140A JP2020511140A (ja) 2020-04-16
JP2020511140A5 JP2020511140A5 (https=) 2021-04-30
JP7155144B2 true JP7155144B2 (ja) 2022-10-18

Family

ID=63523847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550815A Active JP7155144B2 (ja) 2017-03-14 2018-03-14 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物

Country Status (8)

Country Link
US (2) US11872194B2 (https=)
EP (1) EP3595707A4 (https=)
JP (1) JP7155144B2 (https=)
CN (1) CN110520152A (https=)
AU (1) AU2018235945A1 (https=)
CA (1) CA3056396A1 (https=)
MA (1) MA47786A (https=)
WO (1) WO2018170134A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687555A4 (en) * 2017-09-27 2021-07-21 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND CAR-T TISSUE FACTOR TARGETING
WO2022106648A1 (en) 2020-11-20 2022-05-27 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504315A (ja) 1999-07-01 2003-02-04 エール ユニバーシティ 血管新生標的免疫複合体
US20060024730A1 (en) 2002-07-12 2006-02-02 Novo Nordisk A/S TF binding compounds
JP2007500744A (ja) 2003-05-06 2007-01-18 シントニックス・ファーマシューティカルズ・インコーポレーテッド 免疫グロブリンキメラ単量体−二量体ハイブリッド
JP2013534427A (ja) 2010-07-09 2013-09-05 バイオジェン アイデック ヘモフィリア インコーポレイテッド キメラの凝固因子

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5166197A (en) 1990-07-17 1992-11-24 Kenney Malcolm E Phthalocyanine photosensitizers for photodynamic therapy
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
BR112018001148A2 (pt) * 2015-08-06 2018-09-11 Glycotope Gmbh heterômeros compreendendo proteínas de fusão com domínios de anticorpos
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504315A (ja) 1999-07-01 2003-02-04 エール ユニバーシティ 血管新生標的免疫複合体
US20060024730A1 (en) 2002-07-12 2006-02-02 Novo Nordisk A/S TF binding compounds
JP2007500744A (ja) 2003-05-06 2007-01-18 シントニックス・ファーマシューティカルズ・インコーポレーテッド 免疫グロブリンキメラ単量体−二量体ハイブリッド
JP2013534427A (ja) 2010-07-09 2013-09-05 バイオジェン アイデック ヘモフィリア インコーポレイテッド キメラの凝固因子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res, 2008, Vol.68, No.10, pp.3863-3872
Oncotarget, 2017, Vol.8, No,1, pp.1481-1494
Trends in Biotechnology, 2016, Vol.34, No.11, pp.895-908

Also Published As

Publication number Publication date
AU2018235945A1 (en) 2019-10-17
JP2020511140A (ja) 2020-04-16
US20200085922A1 (en) 2020-03-19
MA47786A (fr) 2020-01-22
EP3595707A1 (en) 2020-01-22
US11872194B2 (en) 2024-01-16
WO2018170134A1 (en) 2018-09-20
CN110520152A (zh) 2019-11-29
EP3595707A4 (en) 2021-01-13
CA3056396A1 (en) 2018-09-20
US20240123042A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
JP7820448B2 (ja) 新規のサイトカインプロドラッグ
US11033634B2 (en) Light chain variable regions
AU2015225867B2 (en) Methods and compositions for modifying the immune response
JP7284187B2 (ja) 抗体－薬物コンジュゲートおよびがんの処置のためのそれらの使用
US9498509B2 (en) TIMP3 as VEGF inhibitor
JP2022512778A (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
AU2015218633A1 (en) Anti-DLL3 antibodies and drug conjugates for use in melanoma
JP2022506310A (ja) 抗ＣＤ７９ｂ抗体、その薬物複合体及びその応用
TW201726175A (zh) 新穎抗密連蛋白（ｃｌａｕｄｉｎ）抗體及使用方法
CN101611053A (zh) 抗血管生成化合物
RU2758160C2 (ru) Новые антитела против фактора xi и их применения
EP1708752B1 (en) Polymer-bound antibody cancer therapeutic agent
US20240123042A1 (en) Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
EP2136831A2 (en) Anti-angiogenic peptides
EP4477236A1 (en) Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
JP5822407B2 (ja) 軟骨・骨破壊抑制剤
CN101287485A (zh) 抗血管生成化合物
JP2014091687A (ja) 軟骨又は骨の破壊の診断薬
HK1200174B (en) Dll3 modulators and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221005

R150 Certificate of patent or registration of utility model

Ref document number: 7155144

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250